These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 34363798)

  • 1. Clinicopathological features and prognostic significance of programmed death ligand 1 in pediatric ALK-positive anaplastic large cell lymphoma: results of the ALCL99 treatment in Japan.
    Iwafuchi H; Nakazawa A; Sekimizu M; Mori T; Osumi T; Iijima-Yamashita Y; Ohki K; Kiyokawa N; Fukano R; Saito AM; Horibe K; Kobayashi R;
    Hum Pathol; 2021 Oct; 116():112-121. PubMed ID: 34363798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic Subtypes of Systemic Anaplastic Large Cell Lymphoma Show Distinct Differences in PD-L1 Expression and Regulatory and Cytotoxic T Cells in the Tumor Microenvironment.
    Ferreira CR; Manohar V; Zhao S; Bangs CD; Cherry A; Azevedo RS; Lage LAPC; Pereira J; Zerbini MCN; Gratzinger D; Natkunam Y
    Appl Immunohistochem Mol Morphol; 2020 Jan; 28(1):10-16. PubMed ID: 31809310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD-L1 expression is associated with ALK positivity and STAT3 activation, but not outcome in patients with systemic anaplastic large cell lymphoma.
    Shen J; Li S; Medeiros LJ; Lin P; Wang SA; Tang G; Yin CC; You MJ; Khoury JD; Iyer SP; Miranda RN; Xu J
    Mod Pathol; 2020 Mar; 33(3):324-333. PubMed ID: 31383967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD-1/PD-L1 Pathway and Its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas.
    Xie W; Medeiros LJ; Li S; Yin CC; Khoury JD; Xu J
    Curr Hematol Malig Rep; 2020 Aug; 15(4):372-381. PubMed ID: 32394185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor in urothelial carcinoma.
    Zhong Q; Shou J; Ying J; Ling Y; Yu Y; Shen Z; Zhang Y; Li N; Shi Y; Zhou A
    Future Oncol; 2021 Aug; 17(22):2893-2905. PubMed ID: 34189951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Genetic abnormality and protein expression of C-MYC and PD-L1 in ALK-negative anaplastic large cell lymphoma].
    Wang C; Chen X; Chen XY; You ZJ
    Zhonghua Bing Li Xue Za Zhi; 2021 Jun; 50(6):598-603. PubMed ID: 34078046
    [No Abstract]   [Full Text] [Related]  

  • 7. Prognostic impact of minimal disseminated disease and immune response to NPM-ALK in Japanese children with ALK-positive anaplastic large cell lymphoma.
    Iijima-Yamashita Y; Mori T; Nakazawa A; Fukano R; Takimoto T; Tsurusawa M; Kobayashi R; Horibe K
    Int J Hematol; 2018 Feb; 107(2):244-250. PubMed ID: 29030834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib.
    Yang CY; Liao WY; Ho CC; Chen KY; Tsai TH; Hsu CL; Liu YN; Su KY; Chang YL; Wu CT; Liao BC; Hsu CC; Hsu WH; Lee JH; Lin CC; Shih JY; Yang JC; Yu CJ
    Oncologist; 2020 Aug; 25(8):702-711. PubMed ID: 32386255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and laboratory characteristics of systemic anaplastic large cell lymphoma in Chinese patients.
    Wang YF; Yang YL; Gao ZF; Zhou CJ; Gregg X; Shi YF; Wang J; Yang XF; Ke XY
    J Hematol Oncol; 2012 Jul; 5():38. PubMed ID: 22769020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The expression of PD-L1 in salivary gland carcinomas.
    Vital D; Ikenberg K; Moch H; Rössle M; Huber GF
    Sci Rep; 2019 Sep; 9(1):12724. PubMed ID: 31484986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel model of controlling PD-L1 expression in ALK
    Zhang JP; Song Z; Wang HB; Lang L; Yang YZ; Xiao W; Webster DE; Wei W; Barta SK; Kadin ME; Staudt LM; Nakagawa M; Yang Y
    Blood; 2019 Jul; 134(2):171-185. PubMed ID: 31151983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance and therapeutic potential of the activation of anaplastic lymphoma kinase/protein kinase B/mammalian target of rapamycin signaling pathway in anaplastic large cell lymphoma.
    Gao J; Yin M; Zhu Y; Gu L; Zhang Y; Li Q; Jia C; Ma Z
    BMC Cancer; 2013 Oct; 13():471. PubMed ID: 24112608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive immunohistochemical analysis of tumor microenvironment immune status in esophageal squamous cell carcinoma.
    Hatogai K; Kitano S; Fujii S; Kojima T; Daiko H; Nomura S; Yoshino T; Ohtsu A; Takiguchi Y; Doi T; Ochiai A
    Oncotarget; 2016 Jul; 7(30):47252-47264. PubMed ID: 27322149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD8 expression in anaplastic large cell lymphoma correlates with noncommon morphologic variants and T-cell antigen expression suggesting biological differences with CD8-negative anaplastic large cell lymphoma.
    Shen J; Medeiros LJ; Li S; Wang SA; Lin P; Khanlari M; Iyer SP; Yin CC; Tang G; Jorgensen JL; Hu S; Miranda RN; Xu J
    Hum Pathol; 2020 Apr; 98():1-9. PubMed ID: 32032618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Story of survival in anaplastic large cell lymphoma - sometimes more than the anaplastic lymphoma kinase status: An evaluation of pathologic prognostic factors in 102 cases.
    Agrawal K; Shet T; Sridhar E; Dhende S; Sengar M; Arora B; Laskar S; Gujral S; Menon H; Banavali S
    Indian J Pathol Microbiol; 2017; 60(4):533-540. PubMed ID: 29323068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of the autoantibody response to the ALK oncoantigen in pediatric anaplastic lymphoma kinase-positive anaplastic large cell lymphoma with tumor dissemination and relapse risk.
    Ait-Tahar K; Damm-Welk C; Burkhardt B; Zimmermann M; Klapper W; Reiter A; Pulford K; Woessmann W
    Blood; 2010 Apr; 115(16):3314-9. PubMed ID: 20185586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anaplastic large cell lymphoma: a single institution experience from India.
    Lakshmaiah KC; Guruprasad B; Shah A; Kavitha S; Abraham LJ; Govindbabu K; Aruna Kumari BS; Appaji L
    J Cancer Res Ther; 2013; 9(4):649-52. PubMed ID: 24518711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical significance of programmed death-1 and programmed death-ligand 1 expression in the tumor microenvironment of clear cell renal cell carcinoma.
    Mikami S; Mizuno R; Kondo T; Shinohara N; Nonomura N; Ozono S; Eto M; Tatsugami K; Takayama T; Matsuyama H; Kishida T; Oya M;
    Cancer Sci; 2019 Jun; 110(6):1820-1828. PubMed ID: 30972888
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patterns and prognostic values of programmed cell death-ligand 1 expression and CD8 + T-cell infiltration in small cell carcinoma of the esophagus: a retrospective analysis of 34 years of National Cancer Center data in China.
    Zhang C; Zhang G; Xue L; Zhang Z; Zeng Q; Wu P; Wang L; Yang Z; Zheng B; Tan F; Xue Q; Gao S; Sun N; He J
    Int J Surg; 2024 Jul; 110(7):4297-4309. PubMed ID: 36974732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor-infiltrating immune cell subpopulations and programmed death ligand 1 (PD-L1) expression associated with clinicopathological and prognostic parameters in ependymoma.
    Nam SJ; Kim YH; Park JE; Ra YS; Khang SK; Cho YH; Kim JH; Sung CO
    Cancer Immunol Immunother; 2019 Feb; 68(2):305-318. PubMed ID: 30483834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.